Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 55 results for "lacosamide"

Support for lacosamide as a monotherapy in newly diagnosed epi...

medwireNews : Lacosamide could be suitable as a monotherapy for adults with newly diagnosed epilepsy, say researchers. The drug, which is already approved in the USA and Europe as an adjunctive treatment, met the study's non-inferiority criteria ... MedWire News, 2 days ago

13 images for lacosamide

Pharmaceutical Journal, 1 day ago, 5 months ago
Pharmafile, 5 months ago
Edu Bourse, 5 months ago
Monthly Prescribing Reference, 5 months ago
Edu Bourse, 6 months ago
Monthly Prescribing Reference, 7 months ago
Money Control, 7 months ago
India Infoline, 7 months ago
Money Control, 7 months ago

Pending EC decision: Vimpat, lacosamide, Opinion date: 10-Nov-2016

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Vimpat. The marketing authorisation holder for this medicinal product is ...
 European Medicines Agency3 weeks ago UCB : anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU CHMP as monotherapy for patients with partial-onset seizures  4 Traders3 weeks ago BRIEF-UCB's anti-epileptic drug VIMPAT receives positive opinion by EU CHMP  Reuters UK3 weeks ago UCB's anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU CHMP as monotherapy for patients with partial-onset seizures  PipelineReview3 weeks ago

UCB highlights epilepsy research at the 2016 American Epilepsy Society Annual Meeting

BRUSSELS Data being presented include posters further describing the safety and efficacy profile of VIMPAT® (lacosamide) CV and BRIVIACT® (brivaracetam) CV.2,3,4,6,8 Presentations will also share findings on the current state of the union of ...
 Bio-Medicine1 day ago

Lacosamide (CAS 175481-36-4) Global Market Size, Growth, Analysis, Demand And Forecast To 2020: Market Reports Center

(Before It's News) The Global and Chinese Lacosamide (CAS 175481-36-4) Global Market Research Report provides an overview and the current status of the global Lacosamide (CAS 175481-36-4) industrywith a special focus on the Chinese markets. Key ...
 Before It's News1 month ago Global Epilepsy Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis 2016 - Research and Markets  Minyanville3 weeks ago

Clinical Spectrum of Encephalitis Associated With Antibodies Against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor: Case Series and Review of the Literature

Importance The clinical features of autoimmune encephalitis associated with antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR-Abs) remain poorly defined. Objectives To describe 7 patients with ...
 Journal of the American Medical Association2 weeks ago

Nieuwe geneesmiddelen en andere aanbevelingen CHMP 7-10 november 2016

beoordelingscomité CHMP adviseert de voorwaardelijke vergunning voor Translarna (ataluren) te verlengen. Verder liggen er positieve adviezen voor markttoelating van onder andere de biosimilars Lusduna, Movymia en Terrosa. Positieve adviezen voor ...
 CBG-MEB.nl2 weeks ago

UCB, Inc. v. Accord Healthcare, Inc.

Case Name: , Civ. No. 13-1206-LPS (Consolidated), 2016 U.S. Dist. LEXIS 109362 (D. Del. Aug. 12, 2016) (Stark, J.) Drug Product and Patent(s)-in-Suit: Vimpat® (lacosamide); U.S. Patent No. RE38,551 (the ´551 patent) Nature of the Case and ...
 JD Supra2 weeks ago

Shanghai Pharmaceuticals Released 2016 Q3 Results

- ( ) - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading ...
 Sys-Con Media1 month ago SHANGHAI PHARMACEUTICALS : Released 2016 Q3 Results  4 Traders1 month ago

4 Ways to Manage the Rising Cost of Drugs for Epilepsy and Other Conditions

Research shows that the average price of medications in the U.S. is rising at nearly 10 percent per year. This affects the treatment of epilepsy and other medical conditions. If you or your loved one has epilepsy, then perhaps you will recognize ...
 US News & World Report1 month ago

Chronic Pain Treatment Pipeline Review H2 2016

Chronic Pain Pipeline Review, H2 2016, provides an overview of the Chronic Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of ...
 Before It's News1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less